3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
30
Neoplasm Metastasis
3
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Urologic Diseases
1
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Radiation Injuries
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oligometastatic Prostate Cancer
1
Neoplasm Recurrence, Local
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castrate-sensitive Prostate Cancer
1
Hormone Sensitive Prostate Cancer
1
Genital Neoplasms, Male
1
Gastrointestinal Diseases
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
Cyclophosphamide
26
fludarabine
18
Dexamethasone
17
pembrolizumab
12
Rituximab
11
Etoposide
10
venetoclax
9
pomalidomide
9
Gemcitabine
9
fludarabine phosphate
7
daratumumab
7
Lenalidomide
7
Bortezomib
7
carfilzomib
6
obinutuzumab
5
glofitamab
5
Vincristine
5
Temozolomide
5
Prednisone
5
Nivolumab
5
Immunotherapy, Adoptive
5
Cisplatin
5
Calcium Dobesilate
5
selinexor
4
cemiplimab
4
Doxorubicin
4
Cytarabine
4
Carboplatin
4
zanubrutinib
3
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
Androgen Antagonists
×
90 days
×
Clear all
No trials found.